Blood tests for identifying and monitoring ALK-positive non-small cell lung cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Niki Karachaliou, MD, from the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain, discusses the clinical utility of liquid biopsies for the detection of anaplastic lymphoma kinase gene (ALK) rearrangements and fusions in patients with non-small cell lung cancer.

Share this video